Safety, Tolerability, and Pharmacokinetics of DCR-PDL1 in Adults With Solid Tumors

NCT06504368 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumors, Adult

Interventions

DRUG: DCR-PDL1

Sponsor

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company